Central diabetes insipidus (CDI) is the end result of a number of conditions that affect the hypothalamic-neurohypophyseal system. The known causes include germinoma/craniopharyngioma, Langerhans cell histiocytosis (LCH), local inflammatory, autoimmune or vascular diseases, trauma resulting from surgery or an accident, sarcoidosis, metastases and midline cerebral and cranial malformations. In rare cases, the underlying cause can be genetic defects in vasopressin synthesis that are inherited as autosomal dominant, autosomal recessive or X-linked recessive traits. The diagnosis of the underlying condition is challenging and raises several concerns for patients and parents as it requires long-term follow-up. Proper etiological diagnosis can be achieved via a series of steps that start with clinical observations and then progress to more sophisticated tools. Specifically, MRI identification of pituitary hyperintensity in the posterior part of the sella, now considered a clear marker of neurohypophyseal functional integrity, together with the careful analysis of pituitary stalk shape and size, have provided the most striking findings contributing to the diagnosis and understanding of some forms of ‘idiopathic’ CDI. MRI STIR (short-inversion-time inversion recovery sequencing) is a promising technology for the early identification of LCH-dependent CDI.

Keywords:
Pituitary stalk, Vasopressin, Central diabetes insipidus, Langerhans cell histiocytosis
1.
Maghnie M, Cosi G, Genovese E, Manca-Bitti ML, Cohen A, Zecca S, Tinelli C, Gallucci M, Bernasconi S, Boscherini B, Severi F, Arico M: Central diabetes insipidus in children and young adults. N Engl J Med 2000;343:998–1007.
2.
Hensen J, Buchfelder M: The posterior pituitary and its disease; in Pinchera A, et al (eds): Endocrinology and Metabolism. New York, McGraw-Hill, 2001, pp 99–115.
3.
Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 2005;16:2836–2846.
4.
Bichet DG: Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin Nephrol 2008;28:245–251.
5.
Robinson A, Verbalis J: Posterior pituitary; in Kronenberg H, et al (eds): Williams Textbook of Endocrinology, ed 11. Philadephia, Saunders Elsevier, 2008, pp263–287.
6.
Christensen JH, Rittig S: Familial neurohypophyseal diabetes insipidus – an update. Semin Nephrol 2006;26:209–223.
7.
Barat C, Simpson L, Breslow E: Properties of human vasopressin precursor constructs: inefficient monomer folding in the absence of copeptin as a potential contributor to diabetes insipidus. Biochemistry 2004;43:8191–8203.
8.
De Mota N, Reaux-Le Goazigo A, El Messari S, Chartrel N, Roesch D, Dujardin C, Kordon C, Vaudry H, Moos F, Llorens-Cortes C: Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci USA 2004;101:10464–10469.
9.
Agre P: Nobel lecture. Aquaporin water channels. Biosci Rep 2004;24:127–163.
10.
Engel A, Fujiyoshi Y, Agre P: The importance of aquaporin water channel protein structures. EMBO J 2000;19:800–806.
11.
Robertson GL: Posterior pituitary; in Felig B, Frohman LA (eds): Endocrinology and Metabolism, ed 4. New York, McGraw Hill, 2001, p 234.
12.
Braverman LE, Mancini JP, McGoldrick DM: Hereditary idiopathic diabetes insipidus: a case report with autopsy findings. Ann Intern Med 1965;63:503–508.
13.
Ghirardello S, Garre ML, Rossi A, Maghnie M: The diagnosis of children with central diabetes insipidus. J Pediatr Endocrinol Metab 2007;20:359–375.
14.
Willcutts MD, Felner E, White PC: Autosomal recessive familial neurohypophyseal diabetes insipidus with continued secretion of mutant weakly active vasopressin. Hum Mol Genet 1999;8:1303–1307.
15.
Abu Libdeh A, Levy-Khademi F, Abdulhadi-Atwan M, Bosin E, Korner M, White PC, Zangen DH: Autosomal recessive familial neurohypophyseal diabetes insipidus: onset in early infancy. Eur J Endocrinol 2010;162:221–226.
16.
Ye L, Li X, Chen Y, Sun H, Wang W, Su T, Jiang L, Cui B, Ning G: Autosomal dominant neurohypophyseal diabetes insipidus with linkage to chromosome 20p13 but without mutations in the AVP-NPII gene. J Clin Endocrinol Metab 2005;90:4388–4393.
17.
Christensen JH, Siggaard C, Corydon TJ, Robertson GL, Gregersen N, Bolund L, Rittig S: Differential cellular handling of defective arginine vasopressin (AVP) prohormones in cells expressing mutations of the AVP gene associated with autosomal dominant and recessive familial neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 2004;89:4521–4531.
18.
Davies J, Murphy D: Autophagy in hypothalamic neurones of rats expressing a familial neurohypophysial diabetes insipidus transgene. J Neuroendocrinol 2002;14:629–637.
19.
Russell TA, Ito M, Yu RN, Martinson FA, Weiss J, Jameson JL: A murine model of autosomal dominant neurohypophyseal diabetes insipidus reveals progressive loss of vasopressin-producing neurons. J Clin Invest 2003;112:1697–1706.
20.
Wahlstrom JT, Fowler MJ, Nicholson WE, Kovacs WJ: A novel mutation in the preprovasopressin gene identified in a kindred with autosomal dominant neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 2004;89:1963–1968.
21.
Christensen JH, Siggaard C, Corydon TJ, Robertson GL, Gregersen N, Bolund L, Rittig S: Impaired trafficking of mutated AVP prohormone in cells expressing rare disease genes causing autosomal dominant familial neurohypophyseal diabetes insipidus. Clin Endocrinol 2004;60:125–136.
22.
Ito M, Yu RN, Jameson JL: Mutant vasopressin precursors that cause autosomal dominant neurohypophyseal diabetes insipidus retain dimerization and impair the secretion of wild-type proteins. J Biol Chem 1999;274:9029–9037.
23.
Friberg MA, Spiess M, Rutishauser J: Degradation of wild-type vasopressin precursor and pathogenic mutants by the proteasome. J Biol Chem 2004;279:19441–19447.
24.
Maghnie M, Ghirardello S, De Bellis A, di Iorgi N, Ambrosini L, Secco A, De Amici M, Tinelli C, Bellastella A, Lorini R: Idiopathic central diabetes insipidus in children and young adults is commonly associated with vasopressin-cell antibodies and markers of autoimmunity. Clin Endocrinol 2006;65:470–478.
25.
Pivonello R, De Bellis A, Faggiano A, Di Salle F, Petretta M, Di Somma C, Perrino S, Altucci P, Bizzarro A, Bellastella A, Lombardi G, Colao A: Central diabetes insipidus and autoimmunity: relationship between the occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in a large cohort of patients with central diabetes insipidus of known and unknown etiology. J Clin Endocrinol Metab 2003;88:1629–1636.
26.
Bellastella G, Rotondi M, Pane E, Dello Iacovo A, Pirali B, Dalla Mora L, Falorni A, Sinisi AA, Bizzarro A, Colao A, Chiovato L, De Bellis A: Predictive role of the immunostaining pattern of immunofluorescence and the titers of antipituitary antibodies at presentation for the occurrence of autoimmune hypopituitarism in patients with autoimmune polyendocrine syndromes over a five-year follow-up. J Clin Endocrinol Metab 2010;95:3750–3757.
27.
Maghnie M, Genovese E, Sommaruga MG, Arico M, Locatelli D, Arbustini E, Pezzotta S, Severi F: Evolution of childhood central diabetes insipidus into panhypopituitarism with a large hypothalamic mass: is ‘lymphocytic infundibuloneurohypophysitis’ in children a different entity? Eur J Endocrinol 1998;139:635–640.
28.
De Jersey J, Carmignac D, Le Tissier P, Barthlott T, Robinson I, Stockinger B: Factors affecting the susceptibility of the mouse pituitary gland to CD8 T-cell-mediated autoimmunity. Immunology 2004;111:254–261.
29.
Tzou SC, Lupi I, Landek M, Gutenberg A, Tzou YM, Kimura H, Pinna G, Rose NR, Caturegli P: Autoimmune hypophysitis of SJL mice: clinical insights from a new animal model. Endocrinology 2008;149:3461–3469.
30.
Imura H, Nakao K, Shimatsu A, Ogawa Y, Sando T, Fujisawa I, Yamabe H: Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus. N Engl J Med 1993;329:683–689.
31.
Mirocha S, Elagin RB, Salamat S, Jaume JC: T regulatory cells distinguish two types of primary hypophysitis. Clin Exp Immunol 2009;155:403–411.
32.
Marchand I, Barkaoui MA, Garel C, Polak M, Donadieu J: Central diabetes insipidus as the inaugural manifestation of Langerhans cell histiocytosis: natural history and medical evaluation of 26 children and adolescents. J Clin Endocrinol Metab 2011;96:1352–1360.
33.
Rutishauser J, Kopp P, Gaskill MB, Kotlar TJ, Robertson GL: Clinical and molecular analysis of three families with autosomal dominant neurohypophyseal diabetes insipidus associated with a novel and recurrent mutations in the vasopressin-neurophysin II gene. Eur J Endocrinol 2002;146:649–656.
34.
Batista SL, Moreira AC, Antunes-Rodrigues J, Castro M, Elias LL, Elias PC: Clinical features and molecular analysis of arginine-vasopressin neurophysin II gene in long-term follow-up patients with idiopathic central diabetes insipidus. Arq Bras Endocrinol Metabol 2010;54:269–273.
35.
Maghnie M, Altobelli M, Di Iorgi N, Genovese E, Meloni G, Manca-Bitti ML, Cohen A, Bernasconi S: Idiopathic central diabetes insipidus is associated with abnormal blood supply to the posterior pituitary gland caused by vascular impairment of the inferior hypophyseal artery system. J Clin Endocrinol Metab 2004;89:1891–1896.
36.
Grois N, Potschger U, Prosch H, Minkov M, Arico M, Braier J, Henter JI, Janka-Schaub G, Ladisch S, Ritter J, Steiner M, Unger E, Gadner H: Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer 2006;46:228–233.
37.
Maghnie M, Bossi G, Klersy C, Cosi G, Genovese E, Arico M: Dynamic endocrine testing and magnetic resonance imaging in the long-term follow-up of childhood Langerhans cell histiocytosis. J Clin Endocrinol Metab 1998;83:3089–3094.
38.
Donadieu J, Rolon MA, Pion I, Thomas C, Doz F, Barkaoui M, Robert A, Deville A, Mazingue F, David M, Brauner R, Cabrol S, Garel C, Polak M: Incidence of growth hormone deficiency in pediatric-onset Langerhans cell histiocytosis: efficacy and safety of growth hormone treatment. J Clin Endocrinol Metab 2004;89:604–609.
39.
Maghnie M, Villa A, Arico M, Larizza D, Pezzotta S, Beluffi G, Genovese E, Severi F: Correlation between magnetic resonance imaging of posterior pituitary and neurohypophyseal function in children with diabetes insipidus. J Clin Endocrinol Metab 1992;74:795–800.
40.
Leger J, Velasquez A, Garel C, Hassan M, Czernichow P: Thickened pituitary stalk on magnetic resonance imaging in children with central diabetes insipidus. J Clin Endocrinol Metab 1999;84:1954–1960.
41.
Ghirardello S, Malattia C, Scagnelli P, Maghnie M: Current perspective on the pathogenesis of central diabetes insipidus. J Pediatr Endocrinol Metab 2005;18:631–645.
42.
Mootha SL, Barkovich AJ, Grumbach MM, Edwards MS, Gitelman SE, Kaplan SL, Conte FA: Idiopathic hypothalamic diabetes insipidus, pituitary stalk thickening, and the occult intracranial germinoma in children and adolescents. J Clin Endocrinol Metab 1997;82:1362–1367.
43.
Bettendorf M, Fehn M, Grulich-Henn J, Selle B, Darge K, Ludecke DK, Heinrich UE, Saeger W: Lymphocytic hypophysitis with central diabetes insipidus and consequent panhypopituitarism preceding a multifocal, intracranial germinoma in a prepubertal girl. Eur J Pediatr 1999;158:288–292.
44.
Prosch H, Grois N, Bokkerink J, Prayer D, Leuschner I, Minkov M, Gadner H: Central diabetes insipidus: Is it Langerhans cell histiocytosis of the pituitary stalk? A diagnostic pitfall. Pediatr Blood Cancer 2006;46:363–366.
45.
Ghirardello S, Hopper N, Albanese A, Maghnie M: Diabetes insipidus in craniopharyngioma: postoperative management of water and electrolyte disorders. J Pediatr Endocrinol Metab 2006;19(suppl 1):413–421.
46.
Finken MJ, Zwaveling-Soonawala N, Walenkamp MJ, Vulsma T, van Trotsenburg AS, Rotteveel J: Frequent occurrence of the triphasic response (diabetes insipidus/hyponatremia/diabetes insipidus) after surgery for craniopharyngioma in childhood. Horm Res Paediatr 2011;76:22–26.
47.
Repaske DR, Medlej R, Gultekin EK, Krishnamani MR, Halaby G, Findling JW, Phillips JA 3rd: Heterogeneity in clinical manifestation of autosomal dominant neurohypophyseal diabetes insipidus caused by a mutation encoding Ala-1–>Val in the signal peptide of the arginine vasopressin/neurophysin II/copeptin precursor. J Clin Endocrinol Metab 1997;82:51–56.
48.
Barrett TG, Bundey SE, Macleod AF: Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 1995;346:1458–1463.
49.
Giuliano F, Bannwarth S, Monnot S, Cano A, Chabrol B, Vialettes B, Delobel B, Paquis-Flucklinger V: Wolfram syndrome in French population: characterization of novel mutations and polymorphisms in the WFS1 gene. Hum Mutat 2005;25:99–100.
50.
Smith CJ, Crock PA, King BR, Meldrum CJ, Scott RJ: Phenotype-genotype correlations in a series of Wolfram syndrome families. Diabetes Care 2004;27:2003–2009.
51.
Medlej R, Wasson J, Baz P, Azar S, Salti I, Loiselet J, Permutt A, Halaby G: Diabetes mellitus and optic atrophy: a study of Wolfram syndrome in the Lebanese population. J Clin Endocrinol Metab 2004;89:1656–1661.
52.
Baylis PH, Cheetham T: Diabetes insipidus. Arch Dis Child 1998;79:84–89.
53.
Kanno K, Sasaki S, Hirata Y, Ishikawa S, Fushimi K, Nakanishi S, Bichet DG, Marumo F: Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N Engl J Med 1995;332:1540–1545.
54.
Morgenthaler NG, Struck J, Jochberger S, Dunser MW: Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008;19:43–49.
55.
Maghnie M, Genovese E, Bernasconi S, Binda S, Arico M: Persistent high MR signal of the posterior pituitary gland in central diabetes insipidus. AJNR Am J Neuroradiol 1997;18:1749–1752.
56.
Al-Agha AE, Thomsett MJ, Ratcliffe JF, Cotterill AM, Batch JA: Acquired central diabetes insipidus in children: a 12-year Brisbane experience. J Paediatr Child Health 2001;37:172–175.
57.
Alter CA, Bilaniuk LT: Utility of magnetic resonance imaging in the evaluation of the child with central diabetes insipidus. J Pediatr Endocrinol Metab 2002;15(suppl 2):681–687.
58.
Maghnie M, Genovese E, Arico M, Villa A, Beluffi G, Campani R, Severi F: Evolving pituitary hormone deficiency is associated with pituitary vasculopathy: dynamic MR study in children with hypopituitarism, diabetes insipidus, and Langerhans cell histiocytosis. Radiology 1994;193:493–499.
59.
Smith D, McKenna K, Moore K, Tormey W, Finucane J, Phillips J, Baylis P, Thompson CJ: Baroregulation of vasopressin release in adipsic diabetes insipidus. J Clin Endocrinol Metab 2002;87:4564–4568.
60.
Bourque CW: Central mechanisms of osmosensation and systemic osmoregulation. Nat Rev Neurosci 2008;9:519–531.
61.
Secco A, Allegri AE, di Iorgi N, Napoli F, Calcagno A, Bertelli E, Olivieri I, Pala G, Parodi S, Gastaldi R, Rossi A, Maghnie M: Posterior pituitary (PP) evaluation in patients with anterior pituitary defect associated with ectopic PP and septo-optic dysplasia. Eur J Endocrinol 2011;165:411–420.
62.
Maghnie M, Genovese E, Lundin S, Bonetti F, Arico M: Iatrogenic [corrected] extrapontine myelinolysis in central diabetes insipidus: are cyclosporine and 1-desamino-8-D-arginine vasopressin harmful in association? J Clin Endocrinol Metab 1997;82:1749–1751.
63.
Vande Walle J, Stockner M, Raes A, Norgaard JP: Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf 2007;2:232–238.
64.
Kim RJ, Malattia C, Allen M, Moshang T Jr, Maghnie M: Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations. Pediatr Endocrinol Rev 2004;2(suppl 1):115–123.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.